Blueprint Medicines Announces Pricing of Initial Public Offering
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/22/2026
- Wall St rises on the day but falls for the week; bond yields and Iran in focus
- UBS says bull market has further to run
- S&P 500 may pull back before midterms, but Citi says buy the dip
- Global yield relief evaporates as U.S. rates push back toward multi-decade peaks
- BofA's Hartnett sees dollar slump, risk selloff if bond intervention fails
- Applied Optoelectronics sets up $600M at-the-market stock offering
- Fannie Mae loses at least 10 senior executives amid departures - WSJ
- Wall St rises on the day but falls for the week; bond yields and Iran in focus
- One killed, three injured when man attacks Swedish school with sword
- Morgan Stanley course-corrects their semiconductor equipment outlook on demand
Blueprint Medicines (BPMC) IPO Opens Up 30%
April 30, 2015 10:52 AM EDTBlueprint Medicines' (Nasdaq: BPMC) IPO opened for trading at $23.40 after pricing 8,145,834 shares of its common stock at $18.
Goldman, Sachs & Co. and Cowen and Company are acting as joint book-running managers for the offering. JMP Securities is acting as a co-manager for... More
